Search results for "Sclerosis"

showing 10 items of 1583 documents

Elevated levels of 2-arachidonoylglycerol promote atherogenesis in ApoE-/- mice.

2018

Background The endocannabinoid (eCB) 2-arachidonoylglycerol (2-AG) is a known modulator of inflammation and ligand to both, pro-inflammatory cannabinoid receptor 1 (CB1) and anti-inflammatory CB2. While the role of both receptors in atherogenesis has been studied extensively, the significance of 2-AG for atherogenesis is less well characterized. Methods The impact of 2-AG on atherogenesis was studied in two treatment groups of ApoE-/- mice. One group received the monoacylglycerol lipase (MAGL)-inhibitor JZL184 [5 mg/kg i.p.], which impairs 2-AG degradation and thus causes elevated 2-AG levels, the other group received vehicle for four weeks. Simultaneously, both groups were fed a high-chole…

Male0301 basic medicineCCR1Chemokinelcsh:MedicineSmooth Muscle Cells030204 cardiovascular system & hematologyPathology and Laboratory MedicineBiochemistryMonocytesWhite Blood CellsMicechemistry.chemical_compoundChemokine receptorSpectrum Analysis Techniques0302 clinical medicinePiperidinesAnimal CellsCell MovementMedicine and Health SciencesReceptorlcsh:ScienceImmune ResponseJZL184MultidisciplinarybiologyNeurochemistryFlow CytometryLipidsCholesterolSpectrophotometryCytophotometryCellular TypesNeurochemicalsAnatomymedicine.symptomResearch Articlemedicine.medical_specialtyImmune CellsImmunologyMuscle TissueAntigens Differentiation MyelomonocyticInflammationArachidonic AcidsResearch and Analysis MethodsDiet High-FatCell LineGlycerides03 medical and health sciencesSigns and SymptomsApolipoproteins EDiagnostic MedicineAntigens CDInternal medicinemedicineAnimalsOil Red OBenzodioxolesInflammationMuscle CellsBlood CellsMacrophageslcsh:RBiology and Life SciencesCell BiologyAtherosclerosisMonoacylglycerol lipaseBiological Tissue030104 developmental biologyEndocrinologychemistrybiology.proteinlcsh:QEndocannabinoidsNeurosciencePLoS ONE
researchProduct

Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis

2019

Background: Efficient personalized therapy paradigms are needed to modify the disease course and halt gray (GM) and white matter (WM) damage in patients with multiple sclerosis (MS). Presently, promising disease-modifying drugs show impressive efficiency, however, tailored markers of therapy responses are required. Here, we aimed to detect in a real-world setting patients with a more favorable brain network response and immune cell dynamics upon dimethyl fumarate (DMF) treatment. Methods: In a cohort of 78 MS patients we identified two thoroughly matched groups, based on age, disease duration, disability status and lesion volume, receiving DMF (n = 42) and NAT (n = 36) and followed them ove…

Male0301 basic medicineDimethyl FumarateCD8-Positive T-Lymphocytesmultiple sclerosisGastroenterologychemistry.chemical_compound0302 clinical medicineImmunology and AllergyMedicineLongitudinal StudiesGray MatterOriginal ResearchAged 80 and overCerebral CortexDimethyl fumaratemedicine.diagnostic_testMiddle AgedWhite Mattermedicine.anatomical_structureCohortFemaleAdultlcsh:Immunologic diseases. Allergymedicine.medical_specialtyImmunologyFlow cytometryWhite matter03 medical and health sciencesImmune systemAtrophystructural integrityInternal medicineHumansImmunologic FactorsAgedpersonalized therapybusiness.industryMultiple sclerosismedicine.diseasegray matter networksimmunocellular response030104 developmental biologywhite matter networkschemistryNerve Netbusinesslcsh:RC581-607CD8030215 immunologyFrontiers in Immunology
researchProduct

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

2021

Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic mod…

Male0301 basic medicineDimethyl FumarateNeurodegenerativemultiple sclerosis; coronavirus; pneumoniaSeverity of Illness Indexlaw.inventionImmunosuppressive AgentImmunologic Factor0302 clinical medicineNatalizumablawMonoclonalMultiple Sclerosi80 and overLungHumanizedResearch ArticlesAged 80 and overNatalizumabMiddle AgedIntensive care unitHospitalizationSettore MED/26 - NEUROLOGIAIntensive Care UnitsNeurologyMethylprednisoloneNeurologicalPneumonia & InfluenzaInterferonFemaleImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMusc-19 Study GroupMultiple SclerosisAdolescentClinical SciencesIntensive Care UnitClinical NeurologySettore MED/26Antibodies Monoclonal HumanizedAutoimmune DiseaseAntibodiesYoung Adult03 medical and health sciencesClinical ResearchInternal medicineSeverity of illnessmedicineHumansImmunologic FactorsMortalityAdolescent; Adult; Aged; Aged 80 and over; Antibodies Monoclonal Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young AdultAgedNeurology & NeurosurgeryExpanded Disability Status ScaleFingolimod HydrochlorideSARS-CoV-2business.industryMultiple sclerosisNeurosciencesCOVID-19PneumoniaOdds ratiomedicine.diseaseBrain DisordersGood Health and Well Being030104 developmental biologyOcrelizumabInterferonsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hy…

2018

International audience; Background and Aim: Lipoprotein-associated phospholipase A2 (Lp-PLA2) plays a key role in atherosclerosis development. It is considered a marker of increased risk of cardiovascular disease (CVD) and plaque vulnerability. Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated plasma levels of low-density lipoprotein cholesterol and a higher prevalence of early CVD. Our aim was to evaluate the differences in Lp-PLA2 activity in a population of hypercholesterolemic patients with and without definite FH.Methods and Results: Hypercholesterolemic patients were consecutively recruited. Definite FH was defined according to Dutch Lipid Clinic Netwo…

Male0301 basic medicineEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Low density lipoproteinDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyGastroenterologychemistry.chemical_compound0302 clinical medicineVascular inflammationeducation.field_of_studyNutrition and Dieteticsmedicine.diagnostic_testGenetic disorderMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismCardiovascular diseaseLipidsUp-Regulation3. Good healthPhenotypeLow-density lipoproteinApolipoprotein B-100Femalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyStatin treatmentHypercholesterolemiaFamilial hypercholesterolemiaPopulationPhysical examinationHyperlipoproteinemia Type II03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansLipoprotein-associated phospholipase A2Plaque vulnerabilityeducationAgedApolipoprotein A-Ibusiness.industryCholesterol HDLCholesterol LDLStatin treatmentAtherosclerosisCardiovascular riskmedicine.diseaseCross-Sectional Studies030104 developmental biologychemistry1-Alkyl-2-acetylglycerophosphocholine EsteraseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersLipoproteinNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Specific enrichment of 2-arachidonoyl-lysophosphatidylcholine in carotid atheroma plaque from type 2 diabetic patients

2016

IF 3.942; International audience; Background and aims: Diabetic patients are at high risk of stroke and coronary artery disease. Recent data suggest that arachidonic acid metabolism is altered in diabetic conditions and that these alterations contribute to accelerated atherosclerosis. Little is known about how these alterations affect the metabolism and the proportions of different lipid species within the atherosclerotic plaque. The aim of our study was to perform a targeted lipidomic analysis of human atherosclerotic lesions, with a specific focus on PUFA-containing lipid species, to reveal differences in the fatty-acid composition of plaque in diabetic patients compared with non-diabetic…

Male0301 basic medicineEndothelial lipasePathologymedicine.medical_treatmentCoronary Artery DiseaseCarotid endarterectomy030204 cardiovascular system & hematologyCohort StudiesCoronary artery diseasechemistry.chemical_compound0302 clinical medicineEndarterectomy CarotidLysophosphatidylcholineDiabetesMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemPrognosisLipidsPlaque Atherosclerotic3. Good healthStrokeCholesterolArachidonic acidCholesteryl esterFemalelipids (amino acids peptides and proteins)Arachidonic acidCardiology and Cardiovascular Medicinemedicine.medical_specialtyContext (language use)Biology03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemDiabetes mellitusInternal medicinemedicineHumansAgedLysophosphatidylcholinesLipaseAtherosclerosismedicine.disease030104 developmental biologyAtheromaEndocrinologyDiabetes Mellitus Type 2chemistryMultivariate AnalysisEicosanoidsAtherosclerosis
researchProduct

Mediterranean Diet and atherothrombosis biomarkers: a randomized controlled trial

2020

Scope To assess whether following a Mediterranean diet (MedDiet) improves atherothrombosis biomarkers in high cardiovascular risk individuals. Methods and results In 358 random volunteers from the PREvención con DIeta MEDiterránea trial, the 1‐year effects on atherothrombosis markers of an intervention with MedDiet, enriched with virgin olive oil (MedDiet‐VOO; n = 120) or nuts (MedDiet‐Nuts; n = 119) versus a low‐fat control diet (n = 119), and whether large increments in MedDiet adherence (≥3 score points, versus compliance decreases) and intake changes in key food items are associated with 1‐year differences in biomarkers. Differences are observed between 1‐year changes in the MedDiet‐VOO…

Male0301 basic medicineMediterranean dietProcessed meat intakeAtherothrombosisDiet MediterraneanFibrinogenGastroenterologyCardiovascular riskslaw.inventionFood groupEatingchemistry.chemical_compoundClinical trialsRandomized controlled triallawPlateletNitriteAged 80 and overchemistry.chemical_classificationAntithrombinMiddle AgedThrombosisCardiovascular diseasesBiomarker (medicine)FemaleDietaLipoproteins HDLBiotechnologymedicine.drugcardiovascular riskmedicine.medical_specialty03 medical and health sciencesFatty fishMediterranean cookingThrombinMediterranean dietInternal medicineCuina mediterràniamedicineHumansOlive OilAged030109 nutrition & dieteticsMalalties cardiovascularsbusiness.industryFatty acidThrombosisAtherosclerosismedicine.diseaseConfidence intervalDietCross-Sectional Studies030104 developmental biologyEndocrinologychemistryalpha 1-AntitrypsinbusinessBiomarkersFood Science
researchProduct

Anodal tDCS of the swallowing motor cortex for treatment of dysphagia in multiple sclerosis: a pilot open-label study

2017

Swallowing difficulties are a common symptom of multiple sclerosis (MS). The early detection and treatment of dysphagia is critical to prevent complications, including poor nutrition, dehydration, and lung infections. Recently, transcranial direct current stimulation (tDCS) has been proven to be effective in ameliorating swallowing problems in stroke patients. In this pilot study, we aimed to assess safety and efficacy of transcranial direct current stimulation (tDCS) in the treatment of dysphagia in MS patients. We screened 30 patients by using the 10-item DYsphagia in MUltiple Sclerosis (DYMUS) questionnaire, and patients at risk for dysphagia underwent a clinical and fiberoptic endoscopi…

Male0301 basic medicineNeurologyElectrodemedicine.medical_treatmentPilot ProjectsTranscranial Direct Current StimulationSeverity of Illness IndextDCS0302 clinical medicineMultiple SclerosiDeglutition DisorderNeuroradiologyTranscranial direct-current stimulationMotor CortexDysphagiaGeneral MedicineMiddle AgedDysphagiaPsychiatry and Mental healthTreatment Outcomemedicine.anatomical_structureAnesthesiaFemaleNeurosurgerymedicine.symptomHumanMotor cortexAdultmedicine.medical_specialtyMultiple SclerosisDermatologyFollow-Up Studie03 medical and health sciencesSwallowingotorhinolaryngologic diseasesmedicineHumansPilot ProjectElectrodesElectromyographybusiness.industryMultiple sclerosisSwallowingEvoked Potentials Motormedicine.disease030104 developmental biologyNeurology (clinical)Deglutition Disordersbusiness030217 neurology & neurosurgery2708Follow-Up StudiesNeurological Sciences
researchProduct

CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis

2017

Elevated cerebrospinal fluid (CSF), Neurofilament Light (NF-L) and phosphorylated Heavy (pNF-H) chain levels have been found in Amyotrophic Lateral Sclerosis (ALS), with studies reporting a correlation of both neurofilaments (NFs) with the disease progression. Here, we measured NF-L and pNF-H concentrations in the CSF of ALS patients from a single tertiary Center and investigated their relationship with disease-related variables. A total of 190 ALS patients (Bulbar, 29.9%; Spinal, 70.1%; M/F = 1.53) and 130 controls with mixed neurological diseases were recruited. Demographic and clinical variables were recorded, and Delta FS was used to rate the disease progression. Controls were divided i…

Male0301 basic medicineNeurologypNF-HNeurofilamentKaplan-Meier EstimateGastroenterology0302 clinical medicineCerebrospinal fluidNeurofilament ProteinsMedicinePhosphorylationAmyotrophic lateral sclerosisNeuroradiologyNeurofilament ProteinMiddle AgedPrognosisNeurologyArea Under CurveCohortDisease ProgressionFemaleHumanmedicine.medical_specialtyPrognostic variableNeurofilamentPrognosiCSFEnzyme-Linked Immunosorbent AssayFollow-Up StudieDiagnosis Differential03 medical and health sciencesOligoclonal BandInternal medicineHumansAgedInflammationbusiness.industryAmyotrophic Lateral SclerosisOligoclonal BandsBiomarkermedicine.disease030104 developmental biologyROC CurveNF-LNeurology (clinical)ALSDifferential diagnosisbusinessBiomarkers030217 neurology & neurosurgeryAmyotrophic Lateral SclerosiFollow-Up StudiesJournal of Neurology
researchProduct

CD73 Overexpression in Podocytes: A Novel Marker of Podocyte Injury in Human Kidney Disease

2021

The CD73 pathway is an important anti-inflammatory mechanism in various disease settings. Observations in mouse models suggested that CD73 might have a protective role in kidney damage

Male0301 basic medicinePathologyCCR2podocyte030232 urology & nephrologyGene ExpressionKidneyPodocyte0302 clinical medicineFocal segmental glomerulosclerosisMedicineMinimal change diseaseBiology (General)5'-NucleotidaseSpectroscopyAged 80 and overKidneymedicine.diagnostic_testPodocytesGlomerulonephritisGeneral MedicineMiddle AgedComputer Science ApplicationsChemistryProteinuriaminimal change diseasemedicine.anatomical_structureImmunohistochemistryFemaleKidney DiseasesAdultmedicine.medical_specialtyQH301-705.5Receptors CCR2GPI-Linked ProteinsImmunofluorescenceArticleCatalysisInorganic Chemistry03 medical and health sciencesHumansPhysical and Theoretical ChemistryQD1-999Molecular BiologyAgedbusiness.industryOrganic Chemistrymedicine.disease030104 developmental biologyGene Expression RegulationCD73CCR2businessBiomarkersInternational Journal of Molecular Sciences
researchProduct

Anti-Inflammatory Effects of the Mediterranean Diet in the Early and Late Stages of Atheroma Plaque Development

2017

Objective.To evaluate the long-term effects of a Mediterranean diet (MeDiet) intervention on the plasma concentrations of inflammatory and plaque stability-related molecules in elderly people at high risk for cardiovascular disease.Design and Setting. 66 participants from primary care centers affiliated with the Hospital Clinic of Barcelona were randomized into 3 groups: MeDiet plus extra virgin olive oil (EVOO) or nuts and a low-fat diet (LFD). At baseline and at 3 and 5 years, we evaluated the changes in the plasma concentrations of 24 inflammatory biomarkers related to the different stages of the atherosclerotic process by Luminex®.Results.At 3 and 5 years, both MeDiet groups showed a si…

Male0301 basic medicinePathologyMediterranean dietHigh-risk030204 cardiovascular system & hematologyDiet MediterraneanDieta mediterràniaGastroenterology0302 clinical medicineRisk FactorsElderly peopleChemokine CCL4Chemokine CCL5Diet Fat-RestrictedAged 80 and overBioquímica y tecnologíaInterleukin-18Middle AgedInflammatory biomarkersPlaque AtheroscleroticInterleukin-10Lipoproteins LDLBiochemistry and technologyCardiovascular diseasesCardiovascular DiseasesPlasma concentrationCytokinesFemalelcsh:RB1-214medicine.medical_specialtyArticle Subjectmedicine.drug_classImmunologyVascular Cell Adhesion Molecule-1ActivationPrimary careBioquímica i biotecnologiaLow-grade inflammationAnti-inflammatory03 medical and health sciencesMediterranean cookingElderly personsCardiovascular-diseaseInternal medicineCuina mediterrànialcsh:PathologymedicineHumansAgedMarkers030109 nutrition & dieteticsInterleukin-6Malalties cardiovascularsbusiness.industryPatternCell Biologymedicine.diseaseAtherosclerosisAtheromaClinical Study0962-9351Placa ateroscleròticabusiness
researchProduct